MedTrace Logo

S100B in Intensive Care Patients With and Without Traumatic Brain Injury

NCT04501315 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2020-08-06

No results posted yet for this study

Summary

The neurotrophic protein S100B has been promoted as a neuromarker for decades, and to reflect the severity of brain injury. On the other hand, S100B is a tumor marker. The interpretation of its serum levels may be altered by a contribution from extracerebral sources and its renal elimination.

In the present study we investigate the relevance of S100B as a prognostic factor, as well as the correlation with different CT classifications in a large cohort of patients with and without brain injury. Furthermore, we examine whether S100B is elevated in brain tumors.

Conditions

  • Tumor
  • Brain Injuries
  • Trauma Injury
  • Critical Illness
  • Surgery--Complications

Interventions

DIAGNOSTIC_TEST

Blood, cerebrospinal fluid and urine samples

In all subjects, blood (4 mL), cerebrospinal fluid (4mL) and urine (4mL) samples were collected daily as part of the clinical routine at 6:00 AM.

Sponsors & Collaborators

  • University of Erlangen-Nürnberg Medical School

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-01
Primary Completion
2018-12-31
Completion
2019-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04501315 on ClinicalTrials.gov